Axa
GEVA

Axa’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Axa’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-176,224
Closed -$17.2M – 1518
2015
Q1 		$17.2M Buy
176,224
+25,497
+17% +$2.7M 0.07% 287
2014
Q4 		$14M Buy
150,727
+7,067
+5% +$558K 0.06% 322
2014
Q3 		$9.88M Buy
143,660
+19,527
+16% +$1.4M 0.04% 380
2014
Q2 		$13M Sell
124,133
-3,928
-3% -$334K 0.05% 349
2014
Q1 		$10.6M Buy
128,061
+4,230
+3% +$391K 0.05% 368
2013
Q4 		$8.01M Buy
123,831
+20,865
+20% +$1.24M 0.04% 418
2013
Q3 		$6.52M Buy
102,966
+34,788
+51% +$1.71M 0.03% 460
2013
Q2 		$2.86M Buy
+68,178
New +$3.11M 0.02% 618

Axa's GEVA Position: Q2 2015 in Review

Axa sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 176,224 shares — an estimated $17.2M sold.

Axa first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $17.2M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Axa reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Axa sold 176,224 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $17.2M.
  • Axa first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Axa's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $17.2M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Axa's 13F filing for Q2 2015, filed 13 Aug 2015.